Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Chief Financial Officer | July 13, 2017 | July 14, 2017 |
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Finance & CFO | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | Direct | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
IONIS PHARMACEUTICALS INC
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,660 |
Ending reported balance
After 2026-03-17 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-03-16 · Exercise / conversion · Acquired 60,299 · Balance 193,180 Row 2 · 2026-03-16 · Exercise / conversion · Acquired 61,041 · Balance 254,221 Row 3 · 2026-03-16 · Exercise / conversion · Acquired 33,118 · Balance 287,339 Row 4 · 2026-03-16 · Exercise / conversion · Acquired 20,541 · Balance 307,880 Row 5 · 2026-03-16 · Sale · Disposed 205,608 · Balance 102,272 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.70 to $72.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Row 6 · 2026-03-16 · Sale · Disposed 9,440 · Balance 92,832 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.71 to $72.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Row 7 · 2026-03-17 · Sale · Disposed 10,172 · Balance 82,660 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $73.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.60 · Expires 2032-01-02 | Direct | 0 |
Reported balance
After 2026-03-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-03-16 · Exercise / conversion · Disposed 33,118 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.58 · Expires 2033-01-02 | Direct | 5,405 |
Reported balance
After 2026-03-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-03-16 · Exercise / conversion · Disposed 20,541 · Balance 5,405 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.78 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2026-03-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-03-16 · Exercise / conversion · Disposed 61,041 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.89 · Expires 2027-01-01 | Direct | 0 |
Reported balance
After 2026-03-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-16 · Exercise / conversion · Disposed 60,299 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 9, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.70 to $72.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.71 to $72.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $73.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 9 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. F7 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 7 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. F5 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 5 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. F3 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 653 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2013. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 312 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000011 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2013. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2013. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 45,225 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-17-000004 · edgar.xml · derivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,225 Underlying: Common Stock · 45,225 shares Expires 2024-01-02 F2 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 11,306 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 23:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | OtherCommon Stock | 199 | $20.76 | $4,130.64 |
DisclosureSEC source: 0000874015-17-000004 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,747 F1 · kind: Reporting 199 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These199 shares may not be sold until July 2, 2017. F1 · shares: Reporting 199 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2017. These199 shares may not be sold until July 2, 2017. Read SEC document |
| December 05, 2016 Filed Dec 8, 2016 00:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000874015-16-000150 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2016 Filed Dec 8, 2016 00:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,500 | $46.05 | $115,125.00 |
DisclosureSEC source: 0000874015-16-000150 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,548 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| December 05, 2016 Filed Dec 8, 2016 00:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,500 | $11.27 | $28,175.00 |
DisclosureSEC source: 0000874015-16-000150 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 16:56 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000874015-16-000147 · edgar.xml · derivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 16:56 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,500 | $47.50 | $118,750.00 |
DisclosureSEC source: 0000874015-16-000147 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,548 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 16:56 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,500 | $11.27 | $28,175.00 |
DisclosureSEC source: 0000874015-16-000147 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 23:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000874015-16-000145 · edgar.xml · derivative · entry 6 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 23:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,500 | $41.00 | $102,500.00 |
DisclosureSEC source: 0000874015-16-000145 · edgar.xml · nonDerivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,548 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 23:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,500 | $11.27 | $28,175.00 |
DisclosureSEC source: 0000874015-16-000145 · edgar.xml · nonDerivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000874015-16-000145 · edgar.xml · derivative · entry 5 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires 2017-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 2,500 | $38.49 | $96,225.00 |
DisclosureSEC source: 0000874015-16-000145 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,548 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.37 to $38.56, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:52 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,500 | $11.27 | $28,175.00 |
DisclosureSEC source: 0000874015-16-000145 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 1/3/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.